Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381549 | 1.00 | PDPK1 (0.57) | PDPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL30676520 | 1.00 | PDPK1 (0.57) | PDPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL558436 | 0.92 | PDPK1 (0.57) | PDPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL30381711 | 0.92 | PDPK1 (0.57) | PDPK1KDM4EMEN1ALDH1A1MAPT | |
| Methylene Chloride SCHEMBL27807255 | 0.85 | PDPK1 (0.50) | PDPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL31259166 | 0.78 | PDPK1 (0.61) | PDPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL30003169 | 0.76 | BACE1 (0.48) | PDPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL19516842 | 0.76 | BACE1 (0.48) | PDPK1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL24457846 | 0.75 | PDPK1 (0.57) | PDPK1ABL1PIK3CBNOS1DYRK1A | |
| SCHEMBL10833774 | 0.75 | PDPK1 (0.57) | PDPK1MAPTABL1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | claimed |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | IP2IPO INNOVATIONS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4522610-A1 | GCN2 INHIBITORR | IP2IPO Innovations Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| CN-119451955-A | GCN2 inhibitors | IP2IPO创新有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-11-14 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | PDPK1 1859/4885KDM4E 3667/4885MEN1 3838/4885 |
| US-20250340530-A1 | GCN2 INHIBITOR (as amended) | EIF2AK4, GCN1, GCGR | PDPK1 1908/4885KDM4E 3081/4885MEN1 616/4885 |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | PDPK1 183/4885KDM4E 1688/4885MEN1 2304/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | PDPK1 697/4885KDM4E 851/4885MEN1 3113/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | PDPK1 1859/4885KDM4E 3667/4885MEN1 3838/4885 |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | PDPK1 100/4885KDM4E 3828/4885MEN1 3518/4885 |
| US-12331040-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | BCL6, MALT1, BTK | PDPK1 1700/4885KDM4E 345/4885MEN1 1533/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | PDPK1 61/4885KDM4E 1748/4885MEN1 3130/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | PDPK1 281/4885KDM4E 1444/4885MEN1 2987/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | PDPK1 4645/4885KDM4E 834/4885MEN1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.